{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:24:20Z","timestamp":1790987060824,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40271-013-0006-3","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T09:21:20Z","timestamp":1364203280000},"page":"81-92","source":"Crossref","is-referenced-by-count":17,"title":["The Patient Journey in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Therapies: Qualitative Insights Using a Global Ethnographic Approach"],"prefix":"10.1007","volume":"6","author":[{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Szczudlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Zernovak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Paolantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"issue":"21","key":"6_CR1","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","volume":"89","author":"Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group","year":"1997","unstructured":"Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89(21):1616\u201320.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"6_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"6_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197\u2013203.","journal-title":"Leukemia"},{"issue":"15 suppl","key":"6_CR4","first-page":"417s","volume":"30","author":"A Hochhaus","year":"2012","unstructured":"Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. ASCO Meeting Abstracts. 2012;30(15 suppl):417s.","journal-title":"ASCO Meeting Abstracts"},{"issue":"24","key":"6_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med"},{"issue":"s2","key":"6_CR6","first-page":"348","volume":"95","author":"MF Botteman","year":"2010","unstructured":"Botteman MF, Stephens J, Coombs J. Projecting the long-term survival of newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP) receiving nilotinib or imatinib. Haematologica. 2010;95(s2):348.","journal-title":"Haematologica"},{"issue":"1","key":"6_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337.","journal-title":"Blood"},{"issue":"35","key":"6_CR8","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041\u201351.","journal-title":"J Clin Oncol"},{"key":"6_CR9","unstructured":"National Comprehensive Cancer Network. Chronic myelogenous leukemia. NCCN Clinical Practice Guidelines in Oncology 2012; v.1. 2013."},{"key":"6_CR10","first-page":"253","volume":"6","author":"N Macdonald","year":"2012","unstructured":"Macdonald N, Shapiro A, Bender C, et al. Experiences and perspectives on the GIST patient journey. Patient Prefer Adherence. 2012;6:253\u201362.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"6_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1067\/mhl.2001.119832","volume":"30","author":"JS Mahoney","year":"2001","unstructured":"Mahoney JS. An ethnographic approach to understanding the illness experiences of patients with congestive heart failure and their family members. Heart Lung. 2001;30(6):429\u201336.","journal-title":"Heart Lung"},{"key":"6_CR12","first-page":"248","volume-title":"Handbook of qualitative research","author":"P Atkinson","year":"1994","unstructured":"Atkinson P, Hammersley M. Ethnography and participant observation. In: Denzin NK, Lincoln YS, editors. Handbook of qualitative research. Thousand Oaks: Sage Publications, Inc.; 1994. p. 248\u201361."},{"issue":"6998","key":"6_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bmj.311.6998.182","volume":"311","author":"N Mays","year":"1995","unstructured":"Mays N, Pope C. Qualitative research: observational methods in health care settings. BMJ. 1995;311(6998):182\u20134.","journal-title":"BMJ"},{"issue":"3","key":"6_CR14","first-page":"139","volume":"3","author":"MW Boeri","year":"2009","unstructured":"Boeri MW, Harbry L, Gibson D. A qualitative exploration of trajectories among suburban users of methamphetamine. J Ethnogr Qual Res. 2009;3(3):139\u201351.","journal-title":"J Ethnogr Qual Res"},{"issue":"2","key":"6_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval"},{"issue":"2","key":"6_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1547-5069.1999.tb00455.x","volume":"31","author":"JM Morse","year":"1999","unstructured":"Morse JM, Penrod J. Linking concepts of enduring, uncertainty, suffering, and hope. Image J Nurs Sch. 1999;31(2):145\u201350.","journal-title":"Image J Nurs Sch"},{"issue":"9","key":"6_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1023\/A:1008284006045","volume":"8","author":"PN Butow","year":"1997","unstructured":"Butow PN, Maclean M, Dunn SM, et al. The dynamics of change: cancer patients\u2019 preferences for information, involvement and support. Ann Oncol. 1997;8(9):857\u201363.","journal-title":"Ann Oncol"},{"issue":"2\u20133","key":"6_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0738-3991(99)00040-3","volume":"39","author":"CL McWilliam","year":"2000","unstructured":"McWilliam CL, Brown JB, Stewart M. Breast cancer patients\u2019 experiences of patient-doctor communication: a working relationship. Patient Educ Couns. 2000;39(2\u20133):191\u2013204.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"6_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1188\/07.ONF.415-424","volume":"34","author":"GC Chi","year":"2007","unstructured":"Chi GC. The role of hope in patients with cancer. Oncol Nurs Forum. 2007;34(2):415\u201324.","journal-title":"Oncol Nurs Forum"},{"issue":"14","key":"6_CR20","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long term therapy. Blood. 2011;117(14):3733\u20136.","journal-title":"Blood"},{"issue":"14","key":"6_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381\u20138.","journal-title":"J Clin Oncol"},{"issue":"22","key":"6_CR22","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401\u201311.","journal-title":"Blood"},{"issue":"2","key":"6_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","volume":"29","author":"JH Moon","year":"2011","unstructured":"Moon JH, Sohn SK, Kim SN, et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol. 2011;29(2):1179\u201385.","journal-title":"Med Oncol"},{"issue":"21","key":"6_CR24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V116.21.644.644","volume":"116","author":"F Guilhot","year":"2010","unstructured":"Guilhot F, Coombs J, Zernovak O, et al. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood. 2010;116(21):644.","journal-title":"Blood"},{"issue":"5","key":"6_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, et al. Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626\u201330.","journal-title":"Leuk Res"},{"issue":"6","key":"6_CR26","first-page":"1047","volume":"3","author":"A Cushing","year":"2007","unstructured":"Cushing A, Metcalfe R. Optimizing medicines management: From compliance to concordance. Ther Clin Risk Manag. 2007;3(6):1047\u201358.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"6_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006199-198109000-00002","volume":"30","author":"MH Mishel","year":"1981","unstructured":"Mishel MH. The measurement of uncertainty in illness. Nurs Res. 1981;30(5):258\u201363.","journal-title":"Nurs Res"},{"issue":"1","key":"6_CR28","first-page":"39","volume":"5","author":"K Herth","year":"1991","unstructured":"Herth K. Development and refinement of an instrument to measure hope. Sch Inq Nurs Pract. 1991;5(1):39\u201351.","journal-title":"Sch Inq Nurs Pract"},{"key":"6_CR29","volume-title":"Manual for the Ways of Coping Questionnaire","author":"S Folkman","year":"1988","unstructured":"Folkman S, Lazarus RS. Manual for the Ways of Coping Questionnaire. Palo Alto: Counseling Psychological Press; 1988."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-013-0006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-013-0006-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-013-0006-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-013-0006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:01:54Z","timestamp":1595581314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-013-0006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s40271-013-0006-3","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]}}}